volrustomig volrustomig PHASE3
Drug Profile
ModalityBispecific
RouteIV
Therapy AreaOncology
Peak Sales Est$2000M
Formulations[]
Companies
AZN (ORIGINATOR)100%
Mechanism: PD-1 + TIGIT dual blockade
Expert: Bispecific antibody simultaneously targeting PD-1 and TIGIT immune checkpoints to enhance anti-tumor T-cell and NK-cell activity.
Everyday: A two-in-one antibody that removes two different brakes on the immune system to fight cancer.
Targets: ["PD-1","TIGIT"]
Programs (2)
IndicationStageKey StudyRegional Status
HCCPHASE3GEMSTONE-301[]
Gastric/GEJPHASE3EDGE-Gastric[]
Notes
PD-1/CTLA-4 bispecific.
Data from Supabase · Updated 2026-03-24